Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
86
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Synthesis and Bioactivity of N-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent

A-Long Cui1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
,
Wen-Fang Sun1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China;2 CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
,
Zhao-Jin Zhong1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
,
Jie Jin1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
,
Si-Tu Xue1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of ChinaCorrespondence[email protected] [email protected]
,
Shuo Wu1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China;2 CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
,
Yu-Huan Li1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China;2 CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
&
Zhuo-Rong Li1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People’s Republic of China
 show all
Pages 3723-3729 | Published online: 15 Sep 2020

References

  • BurwitzBJ, HashiguchiPK, MansouriM, et al. MHC-E–restricted CD8 +T cells target Hepatitis B virus–infected human hepatocytes. J Immunol. 2020;204(8):2169–2176. doi:10.4049/jimmunol.190079532161099
  • CuiX, ZhouM, TanJ, et al. Design, synthesis, and bioactive screen in vitro of cyclohexyl (E)-4-(hydroxyimino)-4-phenylbutanoates and their ethers for anti-hepatitis B virus agents. Molecules. 2019;24(11):2063. doi:10.3390/molecules24112063
  • WangA, WuS, TaoZ, et al. Design, synthesis, and anti-HBV activity of new bis (l-amino acid) ester tenofovir prodrugs. ACS Med Chem Lett. 2019;10(6):991–995. doi:10.1021/acsmedchemlett.9b0018431223460
  • HuJ, ChengJ, TangL, et al. Virological basis for the cure of chronic hepatitis B. ACS Infect Dis. 2019;5(5):659–674. doi:10.1021/acsinfecdis.8b0008129893548
  • ZhangY, ChenB, WangL, et al. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review. Rev Esp Enferm Dig. 2016;108:263–270. doi:10.17235/reed.2016.3995/201527023755
  • CavigliaGP, AbateML, PellicanoR, SmedileA. Chronic hepatitis B therapy: available drugs and treatment guidelines. Minerva Gastroenterol Dietol. 2015;61:61–70.25323305
  • TangL, ZhaoQ, WuS, ChengJ, ChangJ, GuoJT. The current status and future directions of hepatitis B antiviral drug discovery. Expert Opin Drug Discov. 2017;12(1):5–15. doi:10.1080/17460441.2017.125519527797587
  • TestoniB, DurantelD, ZoulimF. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37:33–39. doi:10.1111/liv.1330728052622
  • HarrisRS, LiddamentMT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 2004;4(11):868–877. doi:10.1038/nri148915516966
  • SuspèneR, GuétardD, HenryM, SommerP, Wain-HobsonS, VartanianJP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102(23):8321–8326. doi:10.1073/pnas.040822310215919829
  • NoguchiC, IshinoH, TsugeM, et al. G to A hypermutation of hepatitis B virus. Hepatology. 2005;41(3):626–633. doi:10.1002/hep.2058015726649
  • NguyenDH, GummuluruS, HuJ. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol. 2007;81(9):4465–4472. doi:10.1128/JVI.02510-0617314171
  • NguyenDH, HuJ. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol. 2008;82(14):6852–6861. doi:10.1128/JVI.00465-0818480459
  • MaoR, ZhangJ, JiangD, et al. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol. 2011;85(2):1048–1057. doi:10.1128/JVI.01998-1021084489
  • CenS, PengZG, LiXY, et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem. 2010;285(22):16546–16552. doi:10.1074/jbc.M109.08530820363737
  • PengZG, ZhaoZY, LiYP, et al. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology. 2011;53(4):1080–1089. doi:10.1002/hep.2416021480314
  • WangH, ZhongM, LiY, et al. APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity. Antiviral Res. 2019;165:23–33. doi:10.1016/j.antiviral.2019.03.00530862444
  • WangX, AoZ, Danappa JayappaK, ShiB, KobingerG, YaoX. R88-APOBEC3Gm inhibits the replication of both drug-resistant strains of HIV-1 and viruses produced from latently infected cells. Mol Ther Nucleic Acids. 2014;3:e151. doi:10.1038/mtna.2014.224594845
  • HanYX, XueR, ZhaoW, et al. Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection. Antiviral Res. 2005;68(3):147–153. doi:10.1016/j.antiviral.2005.09.00216280177
  • GaoLM, HanYX, WangYP, et al. Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. J Med Chem. 2011;54(3):869–876. doi:10.1021/jm101325h21218816
  • HuangSX, MouJF, LuoQ, et al. Anti-hepatitis B virus activity of esculetin from microsorium fortune in vitro and in vivo. Molecules. 2019;24(19):3475. doi:10.3390/molecules24193475
  • ZhaoD, WangX, LouG, et al. APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems. Virus Res. 2010;151(2):213–219. doi:10.1016/j.virusres.2010.05.00920510315

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.